GLP-1 drugs slow biological aging by reducing visceral fat, not through direct anti-aging mechanisms

GLP-1 receptor agonists slow biological aging as measured by epigenetic clocks, a finding that reveals far more about the cost of excess visceral fat than about the drugs themselves. A 32-week trial of 108 adults with HIV-associated lipohypertrophy—chronic abdominal fat accumulation—showed that weekly semaglutide injections produced a 9% slowing of epigenetic aging on the DunedinPACE clock, with broad improvements in inflammation, metabolic health, and all-cause mortality markers on the PCGrimAge clock. The mechanism is straightforward: by reducing ectopic fat around organs, GLP-1 drugs suppress chronic immune activation and the inflammatory signals that drive accelerated aging. The critical insight is that any sustained loss of visceral fat—via diet, exercise, or pharmacology—produces equivalent benefits. For the longevity-conscious reader, this underscores an uncomfortable truth: abdominal fat is not a cosmetic problem but an aging accelerant that no supplement sidesteps.